Introduction {#sec1-2331216518822198}
============

Tinnitus is the perception of sound in the absence of an external sound source. Its prevalence is 10% to 15% in the general population, increasing with age and after noise exposure ([@bibr14-2331216518822198]). Tinnitus severely impairs the quality of life in 1% to 2% of people and is frequently associated with depression, anxiety, and insomnia ([@bibr30-2331216518822198]; [@bibr32-2331216518822198]).

The exact pathophysiology of tinnitus remains unclear. Neuroplastic changes occurring in the brain following auditory sensory deafferentation alter neural processing ([@bibr2-2331216518822198]; [@bibr23-2331216518822198]; [@bibr43-2331216518822198]). High-frequency cochlear hearing loss reduces cochlear nerve signaling downregulating the inhibitory cortical processes leading to hyperexcitability within the central auditory structures, especially within the primary auditory cortex (AC; [@bibr9-2331216518822198]; [@bibr34-2331216518822198]). There is also abnormal connectivity and increased activity in non-auditory brain areas, for example, frontal, parietal, and limbic areas, that mediate attention and distress, especially in bothersome tinnitus ([@bibr11-2331216518822198]; [@bibr23-2331216518822198]; [@bibr34-2331216518822198]; [@bibr40-2331216518822198]; [@bibr53-2331216518822198]). Furthermore, the tinnitus percept does not seem to alter the functional connectivity of the AC or other key cortical regions in patients with non-bothersome tinnitus ([@bibr65-2331216518822198]).

No curative therapy for tinnitus exists, although nearly 60 different treatment modalities have been investigated. Specific tinnitus counseling and cognitive behavioral therapy are usually recommended ([@bibr67-2331216518822198]). Possible concurrent depression should be treated, but routine use of antidepressive or other medication should be avoided ([@bibr64-2331216518822198]).

Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive technique that applies magnetic pulses to the scalp and underlying brain causing alterations in neuronal excitability and neurotransmitter systems ([@bibr4-2331216518822198]; [@bibr27-2331216518822198]; [@bibr42-2331216518822198]). Cortical excitability can be increased with high-frequency or decreased with low-frequency rTMS via long-term potentiation or long-term depression-like effects in synaptic efficacy ([@bibr22-2331216518822198]). Besides focal alterations, rTMS induces widespread functional changes in the brain networks connected to the stimulated cortical target and also releases dopamine and endogenous opioids ([@bibr22-2331216518822198]; [@bibr27-2331216518822198]; [@bibr35-2331216518822198]; [@bibr42-2331216518822198]). In tinnitus, the AC is thought to be hyperactive ([@bibr59-2331216518822198]), and thus, low frequency (≤1 Hz) rTMS that reduces cortical excitability has been proposed for the treatment of tinnitus ([@bibr13-2331216518822198]; [@bibr51-2331216518822198]).

Depression and neuropathic pain have been successfully treated with rTMS over the past decade ([@bibr12-2331216518822198]; [@bibr35-2331216518822198]; [@bibr55-2331216518822198]). However, in chronic tinnitus, the evidence is still controversial, although a recent meta-analysis on 720 patients observed moderate efficacy of low-frequency rTMS ([@bibr60-2331216518822198]). Several placebo-controlled trials have shown efficacy of rTMS over temporal or temporoparietal regions ([@bibr5-2331216518822198]; [@bibr16-2331216518822198]; [@bibr18-2331216518822198]; [@bibr26-2331216518822198]; [@bibr39-2331216518822198]; [@bibr41-2331216518822198]; [@bibr51-2331216518822198]; [@bibr54-2331216518822198]), while others have not found significant effects ([@bibr21-2331216518822198]; [@bibr28-2331216518822198]; [@bibr31-2331216518822198]; [@bibr48-2331216518822198], [@bibr49-2331216518822198]; [@bibr52-2331216518822198]; [@bibr58-2331216518822198]).

The role of neuronavigated rTMS (nrTMS) in tinnitus treatment remains an open question. nrTMS can be targeted over the hypermetabolic or hyperactive cortical regions detected by positron emission tomography or functional magnetic resonance imaging (fMRI) or targeted with structural brain MRI ([@bibr29-2331216518822198]). However, nrTMS can be more expensive and time-consuming than non-navigated rTMS. Non-navigated methods are inaccurate (by 1--2 cm) with regard to the anatomical cortical targets actually stimulated ([@bibr3-2331216518822198]; [@bibr33-2331216518822198]). Currently, the few available studies do not demonstrate superiority of nrTMS for tinnitus treatment ([@bibr33-2331216518822198], [@bibr29-2331216518822198], [@bibr31-2331216518822198]; [@bibr46-2331216518822198]). One reason for this may be uncertainty regarding the optimal target for suppressing tinnitus. Yet, nrTMS has shown better results than non-navigated rTMS for the treatment of depression and pain ([@bibr8-2331216518822198]; [@bibr17-2331216518822198]).

This study was part of a larger project evaluating rTMS for the treatment of chronic tinnitus ([@bibr58-2331216518822198], [@bibr57-2331216518822198]) and evaluated whether targeting the region overlying the AC with nrTMS based on individual structural head MRI is superior to non-navigated rTMS using the 10--20 electroencephalogram (EEG) electrode location system ([@bibr33-2331216518822198]). An additional goal was to evaluate long-term effects of rTMS on tinnitus.

Materials and Methods {#sec2-2331216518822198}
=====================

This prospective, randomized, single-blind study on parallel groups was approved by the Ethical Committee for the Hospital District of Southwest Finland (73/1800/2013). Patients gave their written informed consent. The trial took place in the Departments of Ear, Nose and Throat Diseases and Clinical Neurophysiology at Satakunta Central Hospital during 2013--2016. The study was registered on ClinicalTrials.gov (ID NCT 01929837).

Patients {#sec3-2331216518822198}
--------

All tinnitus patients treated in the Department of Ear, Nose and Throat Diseases in Satakunta Central Hospital between January 2012 and March 2013 were searched using patient archives. Inclusion criteria were age between 18 and 65 years, chronic (6 months--10 years), unilateral or bilateral tinnitus with an intensity of at least 4/10 on the Numeric Rating Scale (NRS) during a telephone interview. [Figure 1](#fig1-2331216518822198){ref-type="fig"} shows the patient recruitment process. Patients were randomized for either navigated or non-navigated rTMS. All patients underwent complete audiological and otological investigations and a three-dimensional (3-D) head MRI to exclude possible treatable causes and provide anatomical guidance for nrTMS. There were no tumor findings in the MRIs, but one patient had a minor benign cyst; another had minor unspecified signal changes in the brain. Figure 1.Patient recruitment process. The number of patients are shown, and no patients were lost on follow-up. Pulsatile tinnitus and objective tinnitus were excluded. Other exclusion criteria were magnetically active, metallic intracorporeal appliances (e.g., cochlear implants and cardiac pacemakers); epilepsy, or increased risk of seizure (e.g., brain tumor, stroke, and alcohol abuse); bipolar disorder; severe heart disease; migraine; and pregnancy. Patients were phoned and asked whether they still had intractable tinnitus with an average intensity of at least 4/10 on the NRS from 0 (*no tinnitus*) to 10 (*the worst tinnitus a patient could imagine*). No patients had previously been treated with rTMS.NRS = Numeric Rating Scale; rTMS = repetitive transcranial magnetic stimulation.

Forty patients (20 men and 20 women) of ages 19 to 65 years (mean age of 52.9 years, standard deviation \[*SD*\] = 11.7) with a mean tinnitus duration of 5.8 years (*SD* = 3.2) and a mean intensity of 62.2/100 (*SD* = 12.8) completed the study and were included in the analyses. There were no drop-outs. All patients were right-handed, except for one in the non-navigated group. [Table 1](#table1-2331216518822198){ref-type="table"} lists the characteristics of the patients in both groups. The groups did not differ in any of their baseline characteristics (*p* = .087--1.0). Table 1.The Characteristics of the Patients.CharacteristicsNavigated rTMS group (*n* = 20)Non-navigated rTMS group (*n* = 20)*p* value for between-group comparisonMen, n119.75Age, mean (*SD*), years53.7 (11.3)52.0 (12.3).66Age-group, no. of patients \<50 years66 50--60 years891.0 \>60 years65No. of right-handed patients20191.0No. of smoking patients231.0Duration of tinnitus, mean (*SD*), years4.8 (2.9)6.8 (3.2).087Tinnitus location, no. of patients Right ear53 Left ear36.47 Both ears1211Baseline (first phone contact) NRS tinnitus intensity, mean (*SD*)5.9 (1.2)6.5 (1.4).17Baseline VAS tinnitus intensity, mean (*SD*)59.9 (14.4)64.7 (10.8).24Baseline VAS tinnitus annoyance, mean (*SD*)54.7 (18.3)57.6 (15.1).59Baseline VAS tinnitus distress, mean (*SD*)52.4 (15.5)56.9 (16.4).38Baseline Tinnitus Handicap Inventory score, mean (*SD*)44.3 (20.8)40.2 (16.9).49Baseline Beck Depression Inventory score, median (quartiles)6.0 (4.0--9.0)5.5 (3.0--8.0).39SCID (psychiatric interview), baseline no. of depressed patients111.0Baseline no. of depressed patients with antidepressive medication231.0Baseline Jenkins Sleep Evaluation score, median (quartiles)14.0 (9.0--18.5)13.0 (9.0--15.5).86Baseline hearing right ear, PTA (500--4000 Hz), median (quartiles)19.5 (11.0--29.5)17.0 (7.0--28.0).48Baseline hearing left ear, PTA (500--4000 Hz), median (quartiles)19.0 (8.0--27.5)13.5 (6.0--26.5).47Baseline tinnitus loudness match right ear, median (quartiles), dB sensation level35.0 (20.0--45.0)50.0 (30.0--65.0).13Baseline tinnitus loudness match left ear, median (quartiles), dB sensation level30.0 (20.0--52.5)37.5 (20.0--50.0).92Baseline tinnitus pitch match right ear, median (quartiles), kHz sensation level6.0 (3.0--8.0)8.0 (4.0--8.0).38Baseline tinnitus pitch match left ear, median (quartiles), kHz sensation level6.0 (4.0--6.0)6.0 (4.0--8.0).97Baseline tinnitus pitch, no. of patients Low pitch12 High pitch1417.49 Medium pitch20 Both high and low pitch31Resting motor threshold, mean (*SD*), %62.1 (11.9)59.6 (9.1).58[^1]

Blinding {#sec4-2331216518822198}
--------

Patients were randomized using a random permuted block design for either navigated or non-navigated rTMS. All patients (also in the non-navigated rTMS group) underwent a 3-D head MRI. Measurements of the EEG electrode locations and navigation procedures were done for both groups to avoid patient knowledge of the protocol. In addition, the navigation display was set so that patients could not see it during the sessions. Therefore, the rTMS treatment sessions were conducted exactly in the same manner in both groups from the patients' perspective.

Evaluation Scales {#sec5-2331216518822198}
-----------------

An audiogram (both air and bone thresholds) was measured for decibels (dB) hearing level, and a pure tone average of 500 to 4000 Hz was calculated for both ears at the baseline and after the serial treatment. The loudness (dB) and the pitch (Hz) of tinnitus were psycho-acoustically measured with a clinical audiometer at the baseline, after the 2-week treatment, and 1 and 3 months after the rTMS. At these same time points, patients were evaluated using the Tinnitus Handicap Inventory (THI); scores between 0 (*slight tinnitus*) and 100 (*catastrophic tinnitus*; [@bibr44-2331216518822198]) and a Visual Analog Scale (VAS) scores between 0 (no tinnitus) and 100 (*the worst tinnitus the patient could imagine*; Adamchic, Langguth, Hauptmann, & Tass, 2012) for self-ratings of tinnitus intensity, annoyance, and distress in everyday life. In addition, Global Impression of Change (GIC) was given on a scale between −3 (*very much worse than before treatment*) and + 3 (*very much better than before treatment*), 0 meaning no change. The Beck's Depression Inventory (BDI; [@bibr61-2331216518822198]) and the Jenkins Sleep Evaluation Questionnaire (JSEQ; [@bibr24-2331216518822198]) were used to evaluate mood and sleep. The final control was by telephone at 6 months, including NRS (0--10) concerning tinnitus intensity, THI, and GIC. Of the different evaluation scales, VAS and THI were considered as the primary end point measures. Structured diagnostic psychiatric interviews (Structured Clinical Interview for DSM-IV Disorders \[SCID\] Axis I and II) were performed at the baseline.

rTMS {#sec6-2331216518822198}
----

Navigated rTMS was done with Visor2 navigation system (ANT Neuro, Berlin, Germany) capable of showing in real time the position of the coil and the estimated electric field in relation to the brain. The MagStim Rapid^2^ stimulator (Magstim Co., Whitland, Wales, UK) with an air-cooled figure-of-eight coil giving biphasic pulses was used. Prior to treatment, a head MRI was done for all patients with a 1.5 Tesla Siemens Aera scanner (Siemens, Erlangen, Germany) with T1-weighted 3-D sequence. The AC was determined as described in [@bibr33-2331216518822198]; details of the nrTMS are noted in [Figure 2](#fig2-2331216518822198){ref-type="fig"}. Figure 2.The coil localization with Visor2 navigation system. (a) First, the HG was determined for the individual MRI data set using the anatomical landmarks. Then, the TM was placed perpendicular to the HG on the surface of the 3-D model of the brain. (b) During the first visit to the laboratory, a TS was created. The coil was located so that the centerline of the coil was perpendicular to the superior temporal gyrus, went through to the predefined TM, and the induced electric field best stimulated the auditory cortex. The induced current flow direction of the first quarter cycle of the biphasic pulse pointed downward (the red arrow added in the figure). (c) In each treatment session, the coil was navigated to the position of TS with the help of the reproduce stimuli function in Visor2. The position of the coil was monitored, allowing for a 5-degree and 5-mm shift. If these limits were exceeded, the treatment session was paused, and the coil positioning was corrected.HG = Heschl's gyrus; TM = target marker; TS = target stimulus.

Non-navigated rTMS treatment was based on anatomical landmarks (the International 10--20 EEG electrode location system; [@bibr33-2331216518822198]). First, the T3, C3, and Cz EEG electrode sites were defined. Then, the coil was positioned over the Heschl's gyrus (HG) by moving the coil 2.5 cm upward from T3 on line T3-Cz and then 1.5 cm in the posterior direction perpendicularly to that line.

Before the serial treatment, the resting motor threshold was determined as recommended by International Federation of Clinical Neurophysiology ([@bibr19-2331216518822198]). Motor evoked potentials (MEPs) were recorded from the left hand thenar muscles. An MEP response was defined as an MEP with \> 50 µV peak-to-peak amplitude. The maximum-likelihood threshold-tracking algorithm was used to determine TMS intensity yielding a 50% probability of evoking an MEP ([@bibr7-2331216518822198]). The stimulation was done with the same coil used in the treatment sessions.

Patients were randomly assigned to receive navigated (20 patients) or non-navigated (20 patients) rTMS. Over 2 weeks, 10 treatment sessions were given. Each stimulation session consisted of 4,000 pulses at a continuous 1-Hz rate to the left superior temporal gyrus/AC at 100% of the resting motor threshold. All patients received 10 full sessions, except for 2 patients in the navigated group for whom 1 session was 3,950 or 3,980 pulses, and one patient in the non-navigated group for whom 1 session was only 3,100 pulses (all due to technical problems). In the navigated group, the intensity was lowered to 90%--60% for 13 patients in some sessions, and in the non-navigated group, the intensity was lowered to 90%--70% for 11 patients, because of annoying facial contractions. There were no differences between the treatment groups for the medians of maximal or minimal intensities during rTMS sessions (*p* = .17--.97), except for the maximal intensity during the first rTMS session; it was 90% (range 70%--100%) in nrTMS and 100% (range 80%--100%) in non-navigated rTMS (*p* = .012). The left side was chosen because previous studies have shown that stimulation of the left auditory area is efficient, irrespective of tinnitus location ([@bibr10-2331216518822198]; [@bibr37-2331216518822198]), although some contradictory evidence existed ([@bibr25-2331216518822198]). All patients used ear plugs during the treatment.

Statistical Analysis {#sec7-2331216518822198}
--------------------

All data are presented as a mean with SD or a median with interquartile range (lower and upper quartiles) when describing the data; standard error (SE) is given for the repeated measures analyses. Possible baseline differences were tested using two-sample *t* test or the Wilcoxon rank sum test as appropriate. Normal distribution of the variables was evaluated from studentized residuals visually and tested using the Shapiro--Wilk test. Logarithmic transformation was performed to THI to fulfill the normality assumption. To study whether the mean change had occurred between the baseline and post-treatment assessment points and whether the mean changes were different between the groups, we used a hierarchical linear mixed model (HLMM) with repeated measures, including one within-factor (time), one between-factor (group) with the interaction added using important clinical background factors (gender, grade of tinnitus, duration of tinnitus, age-group: \< 50, 50--60, \> 60 years). Compound symmetry covariance structure was used for time. Because of that, we report adjusted mean (SAS least square means) values with 95% confidence interval (CI). If the normality assumption was not met, the treatment groups were compared with the Wilcoxon rank sum test at each visit, and the Friedman's test was used to study the time effect for the entire study population.

Treatment efficacy was calculated using Cohen's *d* values at follow-up time points against the baseline scores. In addition, the number of responders to rTMS was calculated and defined as patients who showed at least a 30% reduction in tinnitus intensity, annoyance, or distress in the VAS scores at any assessment point ([@bibr15-2331216518822198]). The reduction of 6 points or more in the THI scores was also considered a minimal clinically relevant change ([@bibr66-2331216518822198]). The proportion of responders was compared with Fisher's exact test. Confidence interval (95%) was calculated for the absolute difference of proportions between the groups for the excellent responders, the responders based on the reduction of THI scores, and the responders based on the positive GIC. All tests were performed as two sided with a significance level set at .05. The analyses were performed using the SAS System, Version 9.3 for Windows (SAS Institute Inc., Cary, NC, USA).

Results {#sec8-2331216518822198}
=======

Primary Outcome Measures {#sec9-2331216518822198}
------------------------

Overall, a decrease over 3 months was observed in mean tinnitus intensity (HLMM: *F*~3~ = 7.34, *p* = .0006), annoyance (*F*~3~ = 4.45, *p* = .0093), and distress (*F*~3~ = 5.04, *p* = .0051) VAS scores for tinnitus in the whole study group. However, the only difference between the navigated and the non-navigated group was in tinnitus intensity (*F*~3~ = 2.96, *p* = .0451), favoring the non-navigated rTMS. There were no differences in tinnitus annoyance (*F*~3~ = 2.04, *p* = .13) and distress (*F*~3~ = 1.65, *p* = .19; [Figure 3(a)](#fig3-2331216518822198){ref-type="fig"} to ([c](#fig3-2331216518822198){ref-type="fig"}), [Table 2](#table2-2331216518822198){ref-type="table"}). In both groups, the VAS scores (intensity, annoyance, and distress) improved immediately after treatment and stayed at a lower level for up to the 1- and 3-month time points. The mean tinnitus intensity in NRS units decreased in the non-navigated group from 6.5 (*SD* = 1.4) at the baseline (the first telephone interview) to 5.6 (*SD* = 2.3) at the 6-month control, whereas in the navigated group, it returned to the baseline level from 5.9 (*SD* = 1.2) to 6.1 (*SD* = 1.8). There was a difference between the mean changes over time between the groups (*F*~1~ = 5.46, *p* = .0253) favoring the non-navigated rTMS. Figure 3.The effect of neuronavigated (based on the structural MRI) and non-navigated (based on the 10--20 EEG electrode location system) serial rTMS treatment on patient's self-rated tinnitus intensity (a), annoyance (b), distress (c) in VAS 0--100, and THI scores (d), in time from the beginning of the treatment, the adjusted means (± SE). The mean tinnitus intensity (HLMM: *F*~3~ = 7.34, *p* = .0006); annoyance (*F*~3~ = 4.45, *p* = .0093); and distress (*F*~3~ = 5.04, *p* = .0051) decreased in both groups over time with no differences between the groups, except for the tinnitus intensity (*F*~3~ = 2.96, *p* = .0451) favoring the non-navigated rTMS. There was a reduction (*F*~4~ = 17.30, *p* \< .0001) in the THI scores in both groups over time with no difference between the two groups (*F*~4~ = 0.14, *p* = .97). The reduction in the THI scores was maintained for up to 6 months. See [Table 2](#table2-2331216518822198){ref-type="table"} for details.rTMS = repetitive transcranial magnetic stimulation; THI = Tinnitus Handicap Inventory; VAS = Visual Analog Scale. Table 2.Tinnitus Intensity, Annoyance, and Distress in Visual Analog Scale (0--100) and Tinnitus Handicap Inventory Scores at the Time From the Beginning of the rTMS Treatment, Adjusted Mean, SE.TimeTotal group*SEp* valueNavigated rTMS group*SE*Non-navigated rTMS group*SEp* value for between-group comparison(a) Tinnitus intensity Baseline62.21.960.42.764.12.7.24 After41.94.7.0006 over time48.96.634.86.6.0451 over time 1 month42.74.952.26.933.26.9 3 months47.84.950.06.945.66.9(b) Tinnitus annoyance Baseline49.03.944.84.753.25.4.59 After32.65.6.0093 over time34.47.430.87.8.13 over time 1 month32.75.737.47.628.08.0 3 months38.75.936.17.941.38.3(c) Tinnitus distress Baseline46.03.742.54.549.65.2.38 After30.45.4.0051 over time34.27.126.57.5.19 over time 1 month30.15.535.07.325.37.7 3 months37.35.636.77.537.97.9(d) Tinnitus Handicap Inventory scores Baseline341.6361.9332.2.49 After182.2\<.0001 over time192.9183.1.97 over time 1 month142.7153.6143.7 3 months162.7173.7163.8 6 months132.6133.6133.7[^2]

There was a reduction (*F*~4~ = 17.30, *p* \< .0001) in the THI scores for the entire study group over time with no differences between the two treatment groups (*F*~4~ = 0.14, *p* = .97; [Figure 3(d)](#fig3-2331216518822198){ref-type="fig"}, [Table 2](#table2-2331216518822198){ref-type="table"}). The reduction in the mean THI scores persisted for up to 6 months.

The background variables of gender, duration of tinnitus, grade of tinnitus (THI grade), and age-group were evaluated in the model. Gender had an effect, as women showed higher tinnitus intensity than did men (*F*~1~ = 5.8, *p* = .022). Overall, longer duration and lower THI grade of tinnitus were associated with less annoyance caused by tinnitus (*F*~1~ = 6.2, *p* = .018, *F*~4~ = 4, *p* = .010), respectively. For distress, the only significant background variable was the grade of tinnitus (*F*~4~ = 4, *p* = .010); higher THI grades were associated with more distressing symptoms.

The effect size in Cohen's*d* for tinnitus intensity, calculated between the baseline and the post-treatment time points, ranged between 0.33 and 0.47 after nrTMS and between 0.55 and 1.07 after non-navigated rTMS. [Table 4](#table4-2331216518822198){ref-type="table"} presents all the Cohen's *d* values for the different variables. Table 4.The Effect Size in Cohen's *d* (With 95 % CI) for Tinnitus (a) Intensity, (b) Annoyance, and (c) Distress (Measured in VAS 0--100) Calculated Between the Baseline and Post-treatment Time Points.TimeNavigated rTMS group95% CINon-navigated rTMS group95% CIa. Tinnitus intensity After0.38\[0.19, 0.95\]1.07\[0.44, 1.69\] 1 month0.33\[0.06, 0.73\]1.02\[0.40, 1.65\] 3 months0.47\[0.07, 0.87\]0.55\[0.006, 1.11\]b. Tinnitus annoyance After0.35\[0.15, 0.85\]0.75\[0.14, 1.36\] 1 month0.26\[0.19, 0.71\]0.81\[0.21, 1.42\] 3 months0.31\[0.21, 0.83\]0.37\[0.15, 0.88\]c. Tinnitus distress After0.29\[0.19, 0.77\]0.83\[0.23, 1.42\] 1 month0.31\[0.06, 0.68\]0.78\[0.18, 1.38\] 3 months0.25\[0.16, 0.67\]0.37\[0.16, 0.90\][^3]

The rate of excellent responders (clinically meaningful reductions in all the VAS and THI scores) did not differ significantly between the navigated and the non-navigated treatment groups, but there were more excellent responders in the non-navigated group at the 1-month control (55% vs. 25%, Fisher's exact test *p* = .11, the absolute difference \[navigated rTMS − non-navigated rTMS\] of −30, 95% CI \[−54.9, 2.6\]; Supplement Figure 1, Supplement Table 1). Considering only a 30% reduction in tinnitus intensity after rTMS, there were 65% responders in the non-navigated group and 45% in the navigated group (*p* = .34) and 75% versus 40% (*p* = .054) at the 1-month control. Using a 6-point reduction in the THI scores produced similar responder rates in both groups, namely, 75% responders in the navigated and 80% in the non-navigated group immediately following rTMS (*p* = 1.00, the absolute difference \[navigated rTMS − non-navigated rTMS\] of −5, 95% CI \[−31.3, 21.8\]; Supplement Table 1).

Based on the GIC scale, 8/20 (40%) of patients in the navigated group and 3/20 (15%) in the non-navigated group felt they had clearly benefitted (GIC ≥ + 1) from the treatment (Supplement Table 2, Supplement Figure 2). The groups did not differ (*p* values .37--.87) in GIC values (−3 to + 3) at different evaluation points.

Secondary Outcome Measures and Other Findings {#sec10-2331216518822198}
---------------------------------------------

There were no rTMS treatment-induced changes in hearing for the whole group or between the groups for either ear (Supplement Table 3(a)).

There was an improvement in the psycho-acoustically measured loudness of tinnitus (dB) in the left ear for the whole group (mean values; baseline 42.7 \[*SD* = 21.0\] and the 1-month control 24.4 \[*SD* = 21.7\], *p* = .0023 over time); otherwise, there were no changes in loudness or the pitch of tinnitus in the whole group or between the groups during follow-up (Supplement Table 3(b) and (c)).

There was a small improvement in the BDI and JSEQ scores after treatment for the whole group and in both treatment groups (HLMM: time effect BDI: *F*~2~ = 10.9,*p* = .0002, JSEQ: *F*~2~ = 55.2, *p* \< .0001) but no significant differences between the groups over time ([Table 3](#table3-2331216518822198){ref-type="table"}). Only two patients were diagnosed with current depression in the baseline structured psychiatric interviews (SCID; [Table 1](#table1-2331216518822198){ref-type="table"}). Table 3.Beck's Depression Inventory and Jenkins Sleep Evaluation Questionnaire Scores at the Time From the Beginning of the rTMS Treatment, Median (Lower and Upper Quartiles).TimeNavigated rTMS groupNon-navigated rTMS group*p* value for between-group comparison*p* value for time effect for total group(a) Beck's Depression Inventory scores Baseline6.0 (4.0--9.0)5.5 (3.0--8.0).39 After3.0 (0--8.0)2.0 (1.0--5.5).32 over time.0002 over time 3 months1.5 (0--5.5)2.0 (1.0--5.5)(b) Jenkins Sleep Evaluation Questionnaire scores Baseline14.0 (9.0--18.5)13.0 (9.0--15.5).86 After4.0 (3.0--5.0)4.0 (3.5--5.0).48 over time\< .0001 over time 3 months12.0 (8.5--15.0)11.5 (7.0--15.5)[^4]

There were no major adverse effects, but some patients (approximately two to four patients/each session) reported local inconvenience due to muscle twitching at the stimulation side or mild temporary headache.

Discussion {#sec11-2331216518822198}
==========

Chronic tinnitus improved significantly in both rTMS study groups, but nrTMS did not prove to be superior over non-navigated rTMS. In fact, regarding tinnitus intensity, treatment response was even better in the nonnavigated group, in both VAS and NRS scores, as well as in Cohen's *d* values. An improvement in the psycho-acoustically measured loudness of tinnitus in the left ear was observed for the whole group supporting the findings in VAS and THI scores.

Our main findings are in line with another study on tinnitus comparing nrTMS with non-navigated rTMS ([@bibr46-2331216518822198]). Similar to us, they reported significant improvement of THI and VAS scores in both groups but no differences between the groups. Based on improvement of THI scores at least by 7 points, they had somewhat better responder rates, 92% in the navigated group and 89% in the non-navigated group, compared with our rates of 75% and 80% (THI score reduction at least by 6), respectively. Their protocol differed, though, because they treated 22 patients stimulating both the left AC (2,000 pulses/session) and the left prefrontal cortex (1,000 pulses) in only 4 sessions.

[@bibr31-2331216518822198] compared positron emission tomography-guided nrTMS and sham over the left AC, non-navigated rTMS over the left temporal cortex, and non-navigated rTMS combined over the left frontal and the temporal cortices. There was a significant tinnitus reduction for all three active conditions, but as in our study, the comparison between the treatment groups failed to reach significant differences. In another sham-controlled crossover study, eight patients received active nrTMS and eight patients received active non-navigated rTMS ([@bibr54-2331216518822198]). Tinnitus improved after active rTMS protocols compared with sham, but the two active rTMS procedures were not systemically compared. In the present study, the rather high number of sessions (10) and possible placebo effect may have had a positive effect on the responder rates.

In our study, the effect size of Cohen's *d* for tinnitus intensity after nrTMS indicated a modest treatment effect and after non-navigated rTMS good/excellent effect ([Table 4](#table4-2331216518822198){ref-type="table"}). It may be that the target site for nonnavigated rTMS was more optimal for tinnitus treatment. Recently, it was demonstrated on 12 participants that the stimulation spot used according to the 10--20 EEG system is on average 10.4 mm superior and 10.8 mm posterior to the scalp location with minimal distance to the primary AC, that is, most probably the optimal target to reach the AC ([@bibr62-2331216518822198]). Furthermore, in the non-navigated rTMS treatment group, the coil target was not as precise as in nrTMS; therefore, it might have stimulated slightly different cortical targets in a wider brain area in different patients and sessions than in the navigated rTMS group.

Based on our study and the previous literature, it seems that the coil localization method is not a crucial factor in the treatment outcome of rTMS for tinnitus ([@bibr31-2331216518822198]; [@bibr46-2331216518822198]) for several reasons. First, the optimal target for rTMS stimulation in tinnitus still remains open ([@bibr29-2331216518822198]). The left temporoparietal cortex, overlying the more deeply situated AC, is the most frequently used target. The primary AC is buried deep within this region, so the magnetic field more than likely spreads to the more superficial secondary auditory areas instead of directly influencing the primary AC ([@bibr29-2331216518822198]). Hence, the tinnitus suppressing effect is explained by activation of the functional connections that exist between the secondary and the primary AC ([@bibr13-2331216518822198]). In fact, a recent review on non-invasive neuromodulation emphasizes a brain connectivity network perspective for the therapeutic potential rather than just a local effect at the stimulation target ([@bibr63-2331216518822198]).

Here, for technical reasons, the coil was placed to induce downward electric currents in the brain ([Figure 2](#fig2-2331216518822198){ref-type="fig"}), whereas in our previous studies, the currents were in upward direction ([@bibr56-2331216518822198], [@bibr58-2331216518822198]). The effects of posterior--anterior and anterior--posterior currents in the motor cortex may be mediated by different neuronal circuits ([@bibr20-2331216518822198]; [@bibr45-2331216518822198]), and posterior--anterior current direction is considered more effective than anterior--posterior in inducing MEPs (Andre-Obadia, Mertens, Gueguen, Peyron, & Garcia-Larrea, [@bibr6-2331216518822198]). The effect of current/field direction should be taken into account in future studies on rTMS for tinnitus, as most previous reports have not stated the direction of the main induced electric field.

In addition to the AC, multisite stimulation, including the dorsolateral prefrontal cortex, may increase efficacy ([@bibr36-2331216518822198]; [@bibr38-2331216518822198]). Although non-auditory areas participate in tinnitus pathophysiology, rTMS on non-auditory cortical sites alone may be insufficient for tinnitus treatment ([@bibr46-2331216518822198]).

Second, the cortical area stimulated by rTMS is about 2 × 3 cm large, and interindividual differences in skull--brain relations vary in the same range ([@bibr33-2331216518822198], [@bibr29-2331216518822198]). Hence, the precision of neuronavigation may not be needed if the correct target is not more than 1 cm away from the hotspot of the coil. The primary AC may have been within the rTMS coverage in both our treatment groups, at least through the stimulation of the secondary AC.

Third, the heterogeneity of tinnitus etiology, pathophysiology, and its clinical characteristics make it a difficult condition to treat ([@bibr9-2331216518822198]). Despite several theoretical hypotheses, the exact pathophysiology of tinnitus is still ambiguous. There is a need for a unified theoretical pathophysiological framework that would cover the different tinnitus models, thereby offer a network for the core pathophysiology of tinnitus and rational rTMS treatment designs ([@bibr14-2331216518822198]).

Generally, tinnitus has been associated with different psychiatric disorders, especially depression ([@bibr50-2331216518822198]; [@bibr57-2331216518822198]). So, theoretically, improvements in the THI scores in this study could be due to the treatment effects on depression. This seems unlikely, though, because we did not stimulate the dorsolateral prefrontal cortex, the main target of rTMS for depression ([@bibr35-2331216518822198]). In addition, our patients were not depressed at the baseline ([Table 3](#table3-2331216518822198){ref-type="table"}), and only two patients were diagnosed with a current depression in the structured psychiatric interview ([Table 1](#table1-2331216518822198){ref-type="table"}). Thus, although there was a small improvement in the BDI scores for the whole group, that change was not clinically significant given the low BDI scores (median 6.0--5.5 suggestive for minimal depressive symptoms) at the baseline. JSEQ scores were rather high (median 14.0--13.0) at the baseline, and they dropped to 4.0 at the first control but returned nearly back to the baseline at the 3-month control ([Table 3](#table3-2331216518822198){ref-type="table"}).

This study has certain limitations. There was no placebo group, so the outcomes may partly be due to a placebo effect. However, our research group has previously conducted a placebo-controlled randomized study on the topic with borderline results ([@bibr58-2331216518822198]).

The strengths of our study are the elaborate diagnostic evaluation of tinnitus patients by a multidisciplinary research team and a parallel treatment group design to test the study hypothesis. The rTMS treatment was conducted in the same manner at every step in both groups considering the patient's perspective. Follow-up time was also longer than in most rTMS studies.

Conclusions {#sec12-2331216518822198}
===========

rTMS was effective for chronic tinnitus for up to 6 months, and the method of coil localization was not a critical factor for treatment outcome. One reason is that the exact optimal target for rTMS stimulation in tinnitus remains uncertain. Structural MRI-based nrTMS and the 10--20 EEG system-based targeting of rTMS showed similar main treatment effects. Indeed, the treatment response was even better in the non-navigated rTMS group but only concerning tinnitus intensity. More research on nrTMS for tinnitus is still needed to finally define the most optimal target site(s) and the coil orientation for the most successful tinnitus treatment.
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[^1]: *Note*. NRS = Numeric Rating Scale; PTA = pure tone average; rTMS = repetitive transcranial magnetic stimulation; SCID = Structured Clinical Interview for DSM-IV Disorders; VAS = Visual Analog Scale.

[^2]: *Note*. rTMS = repetitive transcranial magnetic stimulation.

[^3]: *Note*. CI = confidence interval; rTMS = repetitive transcranial magnetic stimulation; VAS = Visual Analog Scale.

[^4]: *Note*. rTMS = repetitive transcranial magnetic stimulation.
